Skip to content

Cardiac Resynchronization Therapy (CRT) Efficacy Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00822146
Enrollment
9
Registered
2009-01-14
Start date
2008-12-31
Completion date
2013-03-31
Last updated
2025-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

CRT

Brief summary

The aim of this research study is the invasive evaluation of CR therapy efficacy in patients treated with an InSync Sentry device using an external monitoring device to obtain important cardiac parameters.

Interventions

DEVICECRT

classified

Sponsors

Medtronic
CollaboratorINDUSTRY
Medtronic Cardiac Rhythm and Heart Failure
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient indicated for InSync Sentry CRT device implant * The patient must be willing and capable of following the study protocol * EF ≤ 40% * Systolic pulmonary artery pressure derived by echocardiography \> 40 * Patients with their device functioning in a bi-ventricular mode, with defibrillation detection and therapy enabled * Marked released transvenous RVCoil lead

Exclusion criteria

* Patients with chronic AF * Patients with unipolar atrial or unipolar right ventricular leads * Patients needing a Lower Rate faster than 110 beats per minute * Patients with an implanted Medtronic Sentry in whom missing one day's fluid-measurement value is undesirable * Patients who cannot tolerate turning off Rate Response during the study * Patients with acute ischemia * Patients whose InSync Sentry battery is at ERI or EOL status * Patients with RAMware downloaded from other studies * Patients with medical conditions that would limit study participation * Patients who are pregnant * Patients enrolled in another study, which could influence the result of this study * Patients on the heart transplantation list or patients with transplanted hearts * Patients is not available for follow-up care * Patients has not signed a consent form * Patients with renal failure needing dialysis * Patients whose compliance can expected to be poor * Patients with a mechanical tricuspid valve * Life expectation \< 12 months * Severe PAOD (peripheral arterial occlusive disease) * Underage patients, pregnant or breast feeding women and female patients not using adequate contraception are excluded from participating in the study Since right after implantation study procedure will follow, patient has to sign the informed consent before the implantation. However the following criteria are device based and can therefore not checked at time of sign off. Therefore lead performance will be checked right after the implant and before the study specific procedure. If

Design outcomes

Primary

MeasureTime frame
classified12 months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026